Afimoxifene
As of the edition of 20 October 2026, Afimoxifene is a small molecule: stopped in 2024; acts on ESR1, ESR2 and ESRRG.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Small molecule
- Registered trials
- 7, 2 stopped early
- Disease areas
- Cancer; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product3 company-target rows are on route A because of Afimoxifene.
See the 3 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 2 | 5 | 3 | 1 | 1 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| BHR Pharma | Lead sponsor of trials | 2017 to now |